2019

Theraclion Demonstrates Its Leadership in Thyroid and Veins None Invasive Treatments

Regulatory News:

THERACLION (ISIN: FR0010120402; Mnemo: ALTHE, eligible PEA-SME) (Paris:ALTHE), an innovative company specializing in the development of medical equipment for treatment by echotherapy including varicose veins, announced today its sales for the year 2019, closing on December 31^st.

David Caumartin, Managing Director of Theraclion, says: ”We are proud to announce a 44% growth on sales in line with our previous guidance. In 2019, Theraclion took important steps for its development and in its strategy. Last February fundraising allowed us to enforce our positioning ambition on vein treatment. 4 key opinion leaders in dedicated veins centers in Europe already trust and use our technology with a pay-per-use business model. Furthermore, the SONOVEIN solution has been acquired by key opinion leaders outside Europe. We are making progress towards an FDA approval for SONOVEIN in 2021. This confirms our ambition to disrupt a $10 billion¹ varicose veins market, leveraging our ability to offer not only a none invasive treatment but also an unmet medical need. Thanks to the refund of echotherapy in Germany on historical cares, Ecopulse solution sales have increased. Theraclion is expected to continue its sales growth in 2020 to reach between 30% and 50% sales growth. This sales growth is expected to carry on the following years to achieve break even within three years.”

Strong growth in sales of Theraclion in 2019: + 44%

Theraclion SA achieved a turnover of € 2,784 thousand in 2019, at the high end of the range announced, with strong growth of 44%. For its first year of sales, nearly 80% of the growth comes from SONOVEIN solution.

Annual Sales / K€		2019		2018		Variation
Systems sales		2,352		1,622		+45%
Consumables sales		241		180		+34%
Services sales		191